Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates LXEO Bearish with a Setup Score of 31, net conviction 17, actionability 58. How the Setup Score works →
| Total Setup Score | 31 |
|---|---|
| Directional Bias | Bearish |
| Net Conviction | 17 |
| Actionability | 58 (in range) |
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac mu… Read full Trend Edge analysis →
| Current Price | $4.93 |
|---|---|
| Market Cap | $407M |
| Float | 49.1M |
| Shares Outstanding | 82.0M |
| Price/Sales (TTM) | 478.26 |
| vs. Analyst Target | +311.8% to analyst PT |
| Dividend Rate | None |
| Analyst Target Price | $20.30 (7 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | $518,476 | -$5.2M | $518,476 | -$4.6M |
| 2021 | $1.7M | -$50.6M | $1.7M | -$50.6M |
| 2022 | $654,000 | -$59.3M | $654,000 | -$58.0M |
| 2023 | N/A | -$66.4M | -$1.8M | -$64.3M |
| 2024 | N/A | -$98.3M | -$2.0M | -$96.2M |
| 2025 | N/A | -$100.0M | -$2.1M | -$97.7M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Sep 2025 | N/A | -$20.3M |
| Dec 2025 | N/A | -$20.9M |
| Mar 2026 | N/A | -$20.2M |
| Jun 2026 | N/A | -$25.9M |
| Insider Ownership | 0.6% |
|---|---|
| Institutional Ownership | 117.9% |
| Short Float | 33.3% |
| % of All Funds Holding | 1.64% |
| Number of Funds Holding | 143 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $4.72 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $6.50 | Medium-term trend |
| Weekly | 80-Week SMA | $5.63 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $6.47 | Near-term monthly trend |
| Monthly | 20-Month SMA | $5.66 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $7.00 | resistance | 1.06x | 4 months ago |
| $9.90 | resistance | 1.22x | 6 months ago |
| $2.80 | support | 1.14x | 13 months ago |
| $11.40 | resistance | 1.75x | 22 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | 2.23% | 1.34% | 75.00% | 11.20% | -0.83% |
| 1 Day | 2.36% | 1.84% | 58.33% | 15.06% | -9.38% |
| 1 Week | 2.58% | 2.30% | 63.64% | 35.38% | -26.80% |
| 2 Weeks | 1.92% | 1.59% | 54.55% | 57.68% | -55.50% |
| 1 Month | 6.29% | -5.11% | 45.45% | 60.06% | -28.59% |
Next earnings: October 31, 2026 (73 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | -0.04% | 48.9% | 133 |
| Tuesday | 0.12% | 49.7% | 145 |
| Wednesday | 0.15% | 54.2% | 142 |
| Thursday | -0.02% | 52.6% | 137 |
| Friday | 0.23% | 48.2% | 139 |
Institutional holder breakdown coming soon.
Total institutional ownership: 117.9%
Total insider ownership: 0.6%
Founder-led management: R. Nolan Townsend (Chief Executive Officer), Ronald Crystal (Founder & Chief Scientific Adviser)
| Total Filings | 25 |
|---|---|
| Net Value | -$974,186.639 |
| Net Shares Change | 49,309 |
| % of Float | 0.1% |
| C-Suite Filings | 25 |
| Clusters Detected | 4 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer | -$198,093.542 | 3 | 3 sell |
| Bhalla Narinder Pal | Chief Medical Officer | -$98,592.52 | 1 | 1 sell |
| Otero Jose Manuel | Chief Operating Officer | -$53,487.653 | 4 | 4 sell |
| See Tai Sandi | Chief Development Officer | -$34,766.885 | 1 | 1 sell |
| Tamayo Louis Edward | Chief Financial Officer | -$20,838.09 | 1 | 1 sell |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2025-08-20 – 2025-08-20 | 4 | 4 | -$20,445.84 | 4 C-suite |
| 2025-10-17 – 2025-10-17 | 5 | 5 | -$232,887.714 | 5 C-suite |
| 2025-11-20 – 2025-11-20 | 5 | 5 | -$31,499.46 | 5 C-suite |
| 2026-07-01 – 2026-07-01 | 4 | 4 | -$256,576.85 | 4 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2026-07-01 | Townsend Richard Nolan | Chief Executive Officer | -$116,242.56 | Transaction at $4.48, now +10.0% |
| 2026-07-01 | Bhalla Narinder Pal | Chief Medical Officer | -$98,592.52 | Transaction at $4.42, now +11.5% |
| 2026-07-01 | Tamayo Louis Edward | Chief Financial Officer | -$20,838.09 | Transaction at $4.49, now +9.8% |
| 2026-07-01 | Otero Jose Manuel | Chief Operating Officer | -$20,903.68 | Transaction at $4.48, now +10.0% |
| 2026-02-20 | Townsend Richard Nolan | Chief Executive Officer | -$64,924.086 | Transaction at $6.38, now -22.8% |
| 2026-02-20 | Otero Jose Manuel | Chief Operating Officer | -$19,293.955 | Transaction at $6.40, now -22.9% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Lexeo Therapeutics, Inc. Common Stock (LXEO) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for LXEO on Trend Edge →